

INTREPID Alliance Antiviral Clinical Development Landscape: Overview of Priority Viral Families*

As of March 8, 2024, the 60 clinical phase and approved antiviral compounds fall into 8 of 12 viral families with greatest risk of pandemic potential.

Viral Family	Adenoviridae	Arenaviridae	Coronaviridae	Filoviridae	Flaviviridae	Hantaviridae
	Human Adenovirus A-G	Lassa fever Chapare hemorrhagic fever	COVID-19	Ebola	Dengue Japanese encephalitis	X
Viral Family	Nairoviridae	Orthomyxoviridae	Paramyxoviridae	Peribunyaviridae	Picornaviridae	Togaviridae
	Crimean Congo hemorrhagic fever	Influenza	X	X	Rhinovirus Polio	X

X = absence of clinical phase or approved antivirals

*As of March 8, 2024



**Interested
in engaging
with us?**

To improve our listing, developers are invited to submit non-confidential information on their compound candidates. In addition, we welcome all feedback through our online portal.

For more information, contact nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance